Ting Li, Yang Yang Wang, Shan Li, Yunzhe Hu, Zixuan Sun, Cheng Liu
{"title":"干细胞治疗重建牙槽沟的有效性:随机对照试验的系统回顾和荟萃分析。","authors":"Ting Li, Yang Yang Wang, Shan Li, Yunzhe Hu, Zixuan Sun, Cheng Liu","doi":"10.1155/sci/2780065","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objectives:</b> The goal of this study was to examine the existing evidence from randomized controlled trials (RCTs) on the efficacy of cell treatment in alveolar cleft (AC). <b>Design:</b> An electronic search was done for studies published between January 2000 and May 2024 in the PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases. Primary outcomes were the radiographic assessment of bone graft volume, and the secondary outcome of interest was the number of complications after surgery. A random-effects model and fix-effect model were employed to pool effect sizes, and heterogeneity was assessed using <i>I</i> <sup>2</sup> statistics. <b>Results:</b> Four RCTs, comprising 51 patients, were included in the systematic review and meta-analysis. No statistically significant difference in bone volume (MD [mean difference] -0.82; 95% CI [-3.59, 5.24]; <i>p</i>=0.71) when using cells therapy to repair AC compared to using autologous iliac crest bone graft repair AC. Also, there is no difference in postoperative complications (MD 0.66; 95% CI [0.13, 3.39]; <i>p</i>=0.62) between the two groups. In this meta-analysis, cells therapy on alveolar bone grafting produced results comparable to autologous bone grafting in new bone formation rate and complications. <b>Conclusions:</b> In conclusion, this systematic review and meta-analysis appear to indicate no disadvantage to utilizing cell therapy in AC reconstruction versus autologous bone grafting in terms of bone volume or complications.</p>","PeriodicalId":21962,"journal":{"name":"Stem Cells International","volume":"2025 ","pages":"2780065"},"PeriodicalIF":3.8000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972855/pdf/","citationCount":"0","resultStr":"{\"title\":\"Stem Cell Therapy's Efficiency in Reconstructing Alveolar Clefts: A System Review and Meta-Analysis of Randomized Controlled Trials.\",\"authors\":\"Ting Li, Yang Yang Wang, Shan Li, Yunzhe Hu, Zixuan Sun, Cheng Liu\",\"doi\":\"10.1155/sci/2780065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objectives:</b> The goal of this study was to examine the existing evidence from randomized controlled trials (RCTs) on the efficacy of cell treatment in alveolar cleft (AC). <b>Design:</b> An electronic search was done for studies published between January 2000 and May 2024 in the PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases. Primary outcomes were the radiographic assessment of bone graft volume, and the secondary outcome of interest was the number of complications after surgery. A random-effects model and fix-effect model were employed to pool effect sizes, and heterogeneity was assessed using <i>I</i> <sup>2</sup> statistics. <b>Results:</b> Four RCTs, comprising 51 patients, were included in the systematic review and meta-analysis. No statistically significant difference in bone volume (MD [mean difference] -0.82; 95% CI [-3.59, 5.24]; <i>p</i>=0.71) when using cells therapy to repair AC compared to using autologous iliac crest bone graft repair AC. Also, there is no difference in postoperative complications (MD 0.66; 95% CI [0.13, 3.39]; <i>p</i>=0.62) between the two groups. In this meta-analysis, cells therapy on alveolar bone grafting produced results comparable to autologous bone grafting in new bone formation rate and complications. <b>Conclusions:</b> In conclusion, this systematic review and meta-analysis appear to indicate no disadvantage to utilizing cell therapy in AC reconstruction versus autologous bone grafting in terms of bone volume or complications.</p>\",\"PeriodicalId\":21962,\"journal\":{\"name\":\"Stem Cells International\",\"volume\":\"2025 \",\"pages\":\"2780065\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972855/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Stem Cells International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/sci/2780065\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CELL & TISSUE ENGINEERING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem Cells International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/sci/2780065","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究的目的是检查随机对照试验(RCTs)中关于细胞治疗肺泡裂(AC)疗效的现有证据。设计:对2000年1月至2024年5月在PubMed/MEDLINE、Embase、Cochrane Central Register of Controlled Trials和ClinicalTrials.gov数据库中发表的研究进行电子检索。主要结局是植骨体积的影像学评估,次要结局是术后并发症的数量。采用随机效应模型和固定效应模型汇总效应大小,采用i2统计量评估异质性。结果:系统评价和荟萃分析纳入了4项随机对照试验,共51例患者。骨量差异无统计学意义(MD [mean difference] -0.82;95% ci [-3.59, 5.24];p=0.71),而且在术后并发症方面也无差异(MD = 0.66;95% ci [0.13, 3.39];P =0.62)。在这项荟萃分析中,细胞治疗牙槽骨移植在新骨形成率和并发症方面与自体骨移植的结果相当。结论:总之,本系统综述和荟萃分析似乎表明,在骨体积或并发症方面,使用细胞治疗进行AC重建与自体骨移植没有任何劣势。
Stem Cell Therapy's Efficiency in Reconstructing Alveolar Clefts: A System Review and Meta-Analysis of Randomized Controlled Trials.
Objectives: The goal of this study was to examine the existing evidence from randomized controlled trials (RCTs) on the efficacy of cell treatment in alveolar cleft (AC). Design: An electronic search was done for studies published between January 2000 and May 2024 in the PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases. Primary outcomes were the radiographic assessment of bone graft volume, and the secondary outcome of interest was the number of complications after surgery. A random-effects model and fix-effect model were employed to pool effect sizes, and heterogeneity was assessed using I2 statistics. Results: Four RCTs, comprising 51 patients, were included in the systematic review and meta-analysis. No statistically significant difference in bone volume (MD [mean difference] -0.82; 95% CI [-3.59, 5.24]; p=0.71) when using cells therapy to repair AC compared to using autologous iliac crest bone graft repair AC. Also, there is no difference in postoperative complications (MD 0.66; 95% CI [0.13, 3.39]; p=0.62) between the two groups. In this meta-analysis, cells therapy on alveolar bone grafting produced results comparable to autologous bone grafting in new bone formation rate and complications. Conclusions: In conclusion, this systematic review and meta-analysis appear to indicate no disadvantage to utilizing cell therapy in AC reconstruction versus autologous bone grafting in terms of bone volume or complications.
期刊介绍:
Stem Cells International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of stem cell biology and applications. The journal will consider basic, translational, and clinical research, including animal models and clinical trials.
Topics covered include, but are not limited to: embryonic stem cells; induced pluripotent stem cells; tissue-specific stem cells; stem cell differentiation; genetics and epigenetics; cancer stem cells; stem cell technologies; ethical, legal, and social issues.